An international research team led by the Levenberg Laboratory in the Faculty of Biomedical Engineering at the ...

From lab-grown mini-brains to neck surgery, researchers explore how the glymphatic system can help in treating diseases. Read ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the award of an up ...

Home > Pressemitteilung: ROSSMANN and the Braukmann-Wittenberg ... Three million euros for cardiac surgery: The new surgical system enables minimally invasive procedures to be performed with just a ...

ARPA-H award supports the development of an oral prodrug using Seaport’s proprietary Glyph™ platform to address dysfunctional ...

While dry brushing won’t reach the deeper lymph vessels, it can help encourage superficial circulation and support fluid movement when practised consistently. It also builds something arguably just as ...

Seaport Therapeutics and MIPS awarded up to $15 mn from ARPA-H to advance Seaport’s GlyphCele, the first oral therapeutic designed to restore gut lymphatic function: Boston Thur ...

The most common side effects of mRNA vaccines like the COVID-19 shot are well known: soreness, mild fever, and general ...

Unlike traditional sports tape that restricts motion, kinesiology tape stretches with the body and mimics the elasticity of ...

Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.

The project is being led by the Monash Institute of Pharmaceutical Sciences (MIPS) in partnership with long term collaborator, Seaport Therapeutics, and is being backed by up to AUD$21.5M via the ARPA ...

ARPA-H award supports the development of an oral prodrug, based on the Glyph™ platform initially developed at the Monash Institute of Pharmaceutical ...